AU2001283108A1 - Manipulation of arterial-venous identity - Google Patents

Manipulation of arterial-venous identity

Info

Publication number
AU2001283108A1
AU2001283108A1 AU2001283108A AU8310801A AU2001283108A1 AU 2001283108 A1 AU2001283108 A1 AU 2001283108A1 AU 2001283108 A AU2001283108 A AU 2001283108A AU 8310801 A AU8310801 A AU 8310801A AU 2001283108 A1 AU2001283108 A1 AU 2001283108A1
Authority
AU
Australia
Prior art keywords
vein
endothelial cells
section
polynucleotide
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283108A
Other languages
English (en)
Inventor
Dean Y. Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah filed Critical University of Utah
Publication of AU2001283108A1 publication Critical patent/AU2001283108A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
AU2001283108A 2000-08-03 2001-08-03 Manipulation of arterial-venous identity Abandoned AU2001283108A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22275900P 2000-08-03 2000-08-03
US60222759 2000-08-03
PCT/US2001/024405 WO2002011785A2 (fr) 2000-08-03 2001-08-03 Manipulation de l'identite arterioveineuse

Publications (1)

Publication Number Publication Date
AU2001283108A1 true AU2001283108A1 (en) 2002-02-18

Family

ID=22833556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283108A Abandoned AU2001283108A1 (en) 2000-08-03 2001-08-03 Manipulation of arterial-venous identity

Country Status (7)

Country Link
US (2) US20020081284A1 (fr)
EP (1) EP1392333A2 (fr)
JP (1) JP2004505620A (fr)
AU (1) AU2001283108A1 (fr)
CA (1) CA2417982A1 (fr)
IL (1) IL154224A0 (fr)
WO (1) WO2002011785A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP4762889B2 (ja) 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
NZ549787A (en) 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
WO2006034455A2 (fr) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
RU2559532C2 (ru) 2006-11-02 2015-08-10 Акселерон Фарма, Инк. Антагонисты рецептора и лигандов alk1 и их применение
WO2009023185A1 (fr) 2007-08-13 2009-02-19 Vasgene Therapeutics, Inc. Traitement contre le cancer utilisant des anticorps humanisés qui se lient à ephb4
KR20190037355A (ko) 2008-05-02 2019-04-05 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5282847A (en) * 1991-02-28 1994-02-01 Medtronic, Inc. Prosthetic vascular grafts with a pleated structure
AU665813B2 (en) * 1992-05-11 1996-01-18 Sulzer Medizinaltechnik Ag Process and apparatus for producing endoprostheses
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
AU4410296A (en) * 1994-11-29 1996-06-19 Duke University Diagnosis of and therapy for hereditary haemorrhagic telangiectasia
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
CA2252626A1 (fr) * 1996-04-23 1997-10-30 Ortho-Mcneil Pharmaceutical, Inc. Animaux transgeniques presentant une modification au niveau du recepteur de thrombine
DE19637100A1 (de) * 1996-09-12 1998-03-19 Grohe Kg Hans Anschlußeinrichtung für ein wasserdurchströmtes Gerät
US6201168B1 (en) * 1999-08-20 2001-03-13 University Of Iowa Research Foundation Pathogenesis of cardiomyopathy

Also Published As

Publication number Publication date
WO2002011785A2 (fr) 2002-02-14
JP2004505620A (ja) 2004-02-26
IL154224A0 (en) 2003-07-31
WO2002011785A3 (fr) 2002-05-30
CA2417982A1 (fr) 2002-02-14
US20020081284A1 (en) 2002-06-27
US20040209840A1 (en) 2004-10-21
EP1392333A2 (fr) 2004-03-03

Similar Documents

Publication Publication Date Title
Zhang et al. Viral vectors for gene delivery in tissue engineering
US6753321B2 (en) Method of modulating neovascularization
EP1311699B1 (fr) Distribution de facteurs angiogeniques a mediation assuree par virus associe aux adenovirus
AU2001283108A1 (en) Manipulation of arterial-venous identity
JP2007527395A (ja) 血管新生のための骨髄由来細胞および培地の注入方法
Lee et al. Cardiac gene transfer by intracoronary infusion of adenovirus vector—mediated reporter gene in the transplanted mouse heart
US20150203869A1 (en) Adenoviral Vectors for Transduction of Vascular Tissue
CN101319229B (zh) 重组人bFGF和人PDGF-B的双基因腺病毒载体及其用途
EP1307582B1 (fr) Produits de recombinaison d'acide nucleique, cellules vasculaires transformees au moyen de ces produits de recombinaison, compositions pharmaceutiques et procedes les mettant en application afin d'induire l'angiogenese
US7179459B2 (en) Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
Idris et al. Therapeutic angiogenesis for treatment of peripheral vascular disease
Fields et al. Gene therapy in tissue-engineered blood vessels
US20040132190A1 (en) Gene therapy for myocardial ischemia
CA2414328A1 (fr) Promoteurs chimeriques permettant de commander l'expression dans les cellules des muscles lisses
AU2001270614A2 (en) Chimeric promoters for controlling expression in smooth muscle cells
TWI769535B (zh) 基因工程間充質幹細胞及其應用
WO2011154308A1 (fr) Nouvelles compositions et procédés de thérapie cellulaire dans le traitement de la cirrhose
Duan et al. Construction of two-gene modified artificial bone by using recombinant adenovirus
CA2221710A1 (fr) Therapie genique pour ischemie myocardique
ZACCHIGNA et al. IN VIVO GENE TRANSFER WITH AAV VECTORS AS A TOOL TO UNDERSTAND GENE FUNCTION IN BLOOD VESSEL FORMATION
Woolf Congenital Kidney Diseases: Prospects for New Therapies
Appleby Gene Therapy for In-Stent Restenosis: Improving Adenoviral Vector Performance and The Effects of Transforming Growth Factor-β1 Antagonists on Luminal Loss after Stent-Based Intra-Coronary Gene Transfer
Ranjzad Gene Therapy for Neointimal Hyperplasia: A Comparison of Adenovirus-mediated Gene Transfer of Fibromodulin and Decorin as Inhibitors of Neointimal Hyperplasia in an Organ Culture Model of Human Saphenous Vein